Novilase breast therapy granted FDA breakthrough designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FDA granted Breakthrough Device designation to the Novilase Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women seeking a breast conserving procedure.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login